What is ICD-10 code E85.82?

E85.82 is the ICD-10-CM diagnosis code for Wild-type transthyretin-related (ATTR) amyloidosis. A hereditary disease where abnormal transthyretin protein accumulates in the body, particularly affecting the heart and nerves. This is the most common form of hereditary amyloidosis. E85.82 is a billable code, meaning it can be reported on a claim as a primary or secondary diagnosis when supported by documentation. E85.82 is part of the FY2026 ICD-10-CM code set published by the CMS National Center for Health Statistics and used on Medicare, Medicaid, and commercial claims in the United States.

Yes. E85.82 is a billable ICD-10-CM code that can be reported on professional and institutional claims as a primary or secondary diagnosis when the provider documentation supports the specific condition described. Billable codes in ICD-10-CM are coded to the highest level of specificity available for the documented diagnosis. E85.82 is current for fiscal year 2026 and remains in the active CMS ICD-10-CM code set published by the National Center for Health Statistics.

Which HCC does E85.82 map to under V28?

E85.82 maps to CMS-HCC V28 HCC 50 (Amyloidosis, Porphyria, and Other Specified Metabolic Disorders). The category numbers, labels, and conditions come from the CMS-HCC V28 model file for payment year 2026.

2026 ICD-10-CM E85.82: Wild-type

E85.82 maps to CMS-HCC V28 50. A source-labeled RAF reference is available. Confirm the documented diagnosis and applicable coding requirements. MEAT criteria · RAF Calculator · HCC Buddy coding tools

ICD-10-CM Code View

HCC Buddy Code Card

Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.

Code lookupE85.82

Effective periodFY2026 Apr Update (Apr 1-Sep 30)

FY 2026 Apr update / Endocrine, nutritional and metabolic diseases (E00-E89) / Metabolic disorders (E70-E88)

E85.82

Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidance

Wild-type transthyretin-related (ATTR) amyloidosis

A hereditary disease where abnormal transthyretin protein accumulates in the body, particularly affecting the heart and nerves. This is the most common form of hereditary amyloidosis.

Buddy Insight

Overview Risk Models Code Book Documentation Audit Notes Edition comparison

CMS-HCC V28

Mapped

HCC 50

Amyloidosis, Porphyria, and O...

Code-level coefficient reference

CMS-HCC V24

Historical

Not used for standard CY2026 Medicare Advantage payment. Select a historical period to review V24.

Not used for CY2026 payment

ACA/HHS

Mapped

HCC 029

HHS-HCC 029 adult, RAF varies...

Code-level coefficient reference

ESRD/PACE

Mapped

HCC 23

Other Significant Endocrine a...

Code-level coefficient reference

RXHCC

N/A

—

Not risk-adjusted for this model/period.

Not mapped

Code Book Path

Official

E85Amyloidosis E85.8Other amyloidosis E85.82Wild-type transthyretin-related (ATTR) amyloidosis

Inclusion Terms

Official

Senile systemic amyloidosis (SSA)

Excludes 2

Official

Ehlers-Danlos syndromes (Q79.6-)Inherited from E70-E88, E85
Alzheimer's disease (G30.0-)Inherited from E70-E88, E85

Related Codes

Official

E85.81Light chain (AL) amyloidosis E85.89Other amyloidosis

Includes

Official

No Includes notes are included in this display for E85.82. Check the code and parent instructions in the Code Book.

Excludes 1

Official

transitory endocrine and metabolic disorders specific to newborn (P70-P74)Inherited from E00-E89, E70-E88
androgen insensitivity syndrome (E34.5-)Inherited from E00-E89, E70-E88
congenital adrenal hyperplasia (E25.0)Inherited from E00-E89, E70-E88
hemolytic anemias attributable to enzyme disorders (D55.-)Inherited from E00-E89, E70-E88
Marfan syndrome (Q87.4-)Inherited from E00-E89, E70-E88
5-alpha-reductase deficiency (E29.1)Inherited from E00-E89, E70-E88

Code First

Official

No Code First sequencing instructions are included in this display for E85.82. Check the code and parent instructions in the Code Book.

Use Additional

Official

No Use Additional Code instructions are included in this display for E85.82. Check the code and parent instructions in the Code Book.

Code Also

Official

No Code Also instructions are included in this display for E85.82. Check the code and parent instructions in the Code Book.

Buddy Documentation Tip

HCC Buddy guidance

Confirmed ATTR amyloidosis diagnosis (cardiac MRI, technetium pyrophosphate scan, or tissue biopsy)

Documentation that this is WILD-TYPE (not hereditary/mutant) ATTR — negative TTR gene testing

Cardiac involvement assessment (echocardiography, cardiac biomarkers, NT-proBNP)

Functional status and NYHA class

MEAT Support

HCC Buddy guidance

Confirmed ATTR amyloidosis diagnosis (cardiac MRI, technetium pyrophosphate scan, or tissue biopsy)

Documentation that this is WILD-TYPE (not hereditary/mutant) ATTR — negative TTR gene testing

Cardiac involvement assessment (echocardiography, cardiac biomarkers, NT-proBNP)

Functional status and NYHA class

Audit Caution

HCC Buddy guidance

Confusing wild-type ATTR with hereditary ATTR — genetic testing is required to differentiate

Coding only the heart failure or cardiomyopathy without the underlying amyloidosis diagnosis

Using E85.9 (unspecified) when TTR amyloid type is confirmed

Assuming all cardiac amyloidosis is AL type when wild-type ATTR is increasingly common in elderly patients

Common Mistakes

HCC Buddy guidance

E85.1 — Neuropathic heredofamilial amyloidosis: hereditary ATTR with neuropathy — different code from wild-type

E85.81 — Light chain (AL) amyloidosis: different amyloid protein; treatment is chemotherapy, not tafamidis

I42.5 — Other restrictive cardiomyopathy: may be the presentation but does not capture the amyloidosis etiology

E85.0 — Non-neuropathic heredofamilial amyloidosis: hereditary form; genetic testing differentiates

Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →

Is E85.82 an HCC code?

Yes. E85.82 (Wild-type transthyretin-related (ATTR) amyloidosis) maps to HCC 50, Amyloidosis, Porphyria, and Other Specified Metabolic Disorders under the CMS-HCC V28 risk adjustment model, with a source-labeled community non-dual aged reference coefficient of 0.648. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes. It is billable for payment year 2026.

Coder answer: E85.82 is billable and maps to V28 HCC 50, Amyloidosis, Porphyria, and Other Specified Metabolic Disorders. Open it in the Code Book for the tabular path, RAF, and MEAT checklist.

Code: E85.82
Description: Wild-type transthyretin-related (ATTR) amyloidosis
HCC (V28): HCC 50 — Amyloidosis, Porphyria, and Other Specified Metabolic Disorders
RAF reference coefficient: 0.648
Billable: Yes
Payment year: 2026

HCC Category Mapping

V28HCC 50, Amyloidosis, Porphyria, and Other Specified Metabolic Disorders

0.648

ESRDHCC 23, Other Significant Endocrine and Metabolic Disorders

Not separately weighted

These are source-labeled model coefficients, not member totals. A category may still be removed by hierarchy or model cleanup rules. Weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member context, hierarchy and cleanup rules, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains available for historical review.

Work E85.82 in the Code Book — tabular path, V28 RAF reference, and MEAT checklist →

MEAT review for E85.82

For E85.82, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule.

MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
EEvaluate: test results, medication response, or physical findings reviewed by the provider
AAssess: explicit mention in the assessment or plan with acknowledgment of status
TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis

Coder workflow notes

Get the V28 mapping + MEAT cheat sheet

One printable reference: check representative V28 mappings and the documentation reminders your note needs. Free, no card.

Free PDF. No card. Unsubscribe anytime.

What This Code Means

E85.82 is the ICD-10-CM diagnosis code for wild-type transthyretin-related (attr) amyloidosis. A hereditary disease where abnormal transthyretin protein accumulates in the body, particularly affecting the heart and nerves. This is the most common form of hereditary amyloidosis. E85.82 sits in the ICD-10-CM chapter for endocrine, nutritional and metabolic diseases (e00-e89), within the section covering metabolic disorders (e70-e88).

Under the CMS-HCC V28 risk adjustment model, E85.82 maps to Amyloidosis, Porphyria, and Other Specified Metabolic Disorders (HCC 50) with a source-labeled community, non-dual, aged reference coefficient of 0.648. No V24 mapping is shown for E85.82; use the applicable model and payment year when reviewing the V28 mapping. For CY2026 non-PACE Medicare Advantage, CMS uses 100% of the 2024 CMS-HCC model (V28). PACE uses a separate model blend. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes.

Wild-type ATTR (formerly called senile systemic amyloidosis) occurs in elderly patients without genetic mutations. For E85.82, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.

HCC Buddy maintains structured V28 and V24 mapping, source-labeled coefficient references, and MEAT documentation criteria for E85.82 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.

Coding Tips

•Wild-type ATTR (formerly called senile systemic amyloidosis) occurs in elderly patients without genetic mutations
•Document whether this is hereditary or wild-type variant, as treatment approaches differ significantly

Clinical Significance

Wild-type ATTR amyloidosis (formerly senile cardiac amyloidosis) is an increasingly recognized cause of heart failure in elderly patients, caused by age-related misfolding of normal transthyretin protein. The availability of disease-modifying therapy (tafamidis) has made accurate diagnosis and coding essential for treatment access.

Documentation Requirements

✓Confirmed ATTR amyloidosis diagnosis (cardiac MRI, technetium pyrophosphate scan, or tissue biopsy)
✓Documentation that this is WILD-TYPE (not hereditary/mutant) ATTR — negative TTR gene testing
✓Cardiac involvement assessment (echocardiography, cardiac biomarkers, NT-proBNP)
✓Functional status and NYHA class
✓Current treatment (tafamidis, heart failure management)
✓Exclusion of hereditary ATTR by genetic testing

Commonly Confused Codes

•E85.1: Neuropathic heredofamilial amyloidosis: hereditary ATTR with neuropathy: different code from wild-type
•E85.81: Light chain (AL) amyloidosis: different amyloid protein; treatment is chemotherapy, not tafamidis
•I42.5: Other restrictive cardiomyopathy: may be the presentation but does not capture the amyloidosis etiology
•E85.0: Non-neuropathic heredofamilial amyloidosis: hereditary form; genetic testing differentiates